November 17, 2016 - By Pete Kolinski · 0 Comments
AGILE THERAPEUTICS INC (NASDAQ:AGRX) institutional sentiment decreased to 1.33 in 2016 Q2. Its down -0.96, from 2.29 in 2016Q1. The ratio turned negative, as 28 investment professionals started new and increased holdings, while 21 reduced and sold stakes in AGILE THERAPEUTICS INC. The investment professionals in our partner’s database now own: 21.76 million shares, down from 22.36 million shares in 2016Q1. Also, the number of investment professionals holding AGILE THERAPEUTICS INC in their top 10 holdings increased from 3 to 4 for an increase of 1. Sold All: 6 Reduced: 15 Increased: 19 New Position: 9.
Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The company has a market cap of $207.15 million. The Firm is focused in the development and commercialization of prescription contraceptive products. It currently has negative earnings. The Firm has developed a transdermal patch technology, called Skinfusion.
About 37,248 shares traded hands. Agile Therapeutics Inc (NASDAQ:AGRX) has risen 13.20% since April 15, 2016 and is uptrending. It has outperformed by 8.57% the S&P500.
According to Zacks Investment Research, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company’s lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey.”
Proquest Associates Iv Llc holds 15.67% of its portfolio in Agile Therapeutics Inc for 5.06 million shares. Caxton Corp owns 1.58 million shares or 13.57% of their US portfolio. Moreover, Aisling Capital Llc has 4.64% invested in the company for 2.58 million shares. The Sweden-based Investor Ab has invested 1.99% in the stock. Ra Capital Management Llc, a Massachusetts-based fund reported 853,151 shares.#img1#
Ratings analysis reveals 100% of Agile Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Agile Therapeutics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. AGRX was included in 2 notes of analysts from December 30, 2015. Noble Financial initiated the shares of AGRX in a report on Wednesday, December 30 with “Buy” rating. The stock of Agile Therapeutics Inc (NASDAQ:AGRX) earned “Buy” rating by Cantor Fitzgerald on Friday, January 8.
Agile Therapeutics, Inc., incorporated on December 5, 1997, is a women’s health specialty pharmaceutical company. The Firm is focused on the development and commercialization of prescription contraceptive products. The Company’s product candidates are designed to provide women with contraceptive options. The Firm has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.
More important recent Agile Therapeutics Inc (NASDAQ:AGRX) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on May 23, 2014, also Globenewswire.com published article titled: “Agile Therapeutics Announces Plans to Advance Contraceptive Pipeline”, 247Wallst.com published: “Agile Therapeutics Announces Pricing for Secondary Offering” on January 22, 2016. More interesting news about Agile Therapeutics Inc (NASDAQ:AGRX) was released by: Globenewswire.com and their article: “Agile Therapeutics Announces Completion of Patient Recruitment in Twirla(R …” with publication date: August 31, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski